Valuation: Alteogen Inc

Market Cap 18,069B 13.42B 13.42B 11.92B 11.13B 10.14B 19.13B 1,290B 19.3B 135B 52.18B 659B 50.37B 49.28B 2,116B P/E 2026 *
58.3x
P/E 2027 * 45.3x
Enterprise Value 17.57B 13.05M 13.05M 11.59M 10.82M 9.86M 18.6M 1.25B 18.78M 131M 50.75M 641M 48.99M 47.93M 2.06B EV / Sales 2026 *
36x
EV / Sales 2027 * 26.3x
Free-Float
74.44%
Yield 2026 *
0.16%
Yield 2027 * 0.21%
Manager TitleAgeSince
Chief Executive Officer 61 2025-12-25
Director of Finance/CFO 61 2023-03-27
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 71 2008-05-12
Director/Board Member 70 2021-03-28
Director/Board Member 61 2023-03-27
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.76%-3.39%+26.07%+58.90% 410.8B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 488B 362M 362M 322M 300M 274M 516M 34.81B 521M 3.63B 1.41B 17.8B 1.36B 1.33B 57.11B 660B 490M 490M 435M 406M 370M 699M 47.12B 705M 4.92B 1.91B 24.09B 1.84B 1.8B 77.31B
Net income 311B 231M 231M 205M 192M 175M 329M 22.21B 332M 2.32B 898M 11.35B 867M 848M 36.43B 375B 278M 278M 247M 231M 210M 396M 26.74B 400M 2.79B 1.08B 13.67B 1.04B 1.02B 43.87B
Net Debt -495B -367M -367M -326M -305M -278M -524M -35.31B -529M -3.69B -1.43B -18.05B -1.38B -1.35B -57.94B -739B -549M -549M -488M -455M -415M -782M -52.76B -790M -5.51B -2.13B -26.97B -2.06B -2.02B -86.56B
Logo Alteogen Inc
Alteogen Inc is a Korea-based company primarily engaged in the research, development, and sales of biopharmaceuticals. The Company develops, produces, and sells biopharmaceuticals, including biobetters and novel biopharmaceuticals, based primarily on hyaluronidase protein engineering technology, sustained-release biopharmaceutical technology, and next-generation antibody-drug conjugate technology. In addition, the Company is engaged in research, development, and commercialization of biosimilars.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-